Based on change in weight, change in blood glucose, and age at onset of diabetes, we developed and validated a model to determine risk of PC in patients with NOD based on glycemic status (END-PAC model). An independent prospective study is needed to further validate this model, which could contribute to early detection of PC.
Attractive
protein–protein interactions (PPI) in concentrated monoclonal
antibody (mAb) solutions may lead to reversible oligomers (clusters)
that impact colloidal stability and viscosity. Herein, the PPI are
tuned for two mAbs via the addition of arginine (Arg), NaCl, or ZnSO4 as characterized by the structure factor (S
eff(q)) with small-angle X-ray scattering
(SAXS). The SAXS data are fit with molecular dynamics simulations
by placing a physically relevant short-range attractive interaction
on selected beads in coarse-grained 12-bead models of the mAb shape.
The optimized 12-bead models are then used to differentiate key microstructural
properties, including center of mass radial distribution functions
(g
COM(r)), coordination
numbers, and cluster size distributions (CSD). The addition of cosolutes
results in more attractive S
eff(q) relative to the no cosolute control for all systems tested,
with the most attractive systems showing an upturn at low q. Only the All1 model with an attractive site in each Fab
and Fc region (possessing Fab–Fab, Fab–Fc, and Fc–Fc
interactions) can reproduce this upturn, and the corresponding CSDs
show the presence of larger clusters compared to the control. In general,
for models with similar net attractions, i.e., second osmotic virial
coefficients, the size of the clusters increases as the attraction
is concentrated on a smaller number of evenly distributed beads. The
cluster size distributions from simulations are used to improve the
understanding and prediction of experimental viscosities. The ability
to discriminate between models with bead interactions at particular
Fab and Fc bead sites from SAXS simulations, and to provide real-space
properties (CSD and g
COM(r)), will be of interest in engineering protein sequence and formulating
protein solutions for weak PPI to minimize aggregation and viscosities.
The ability to design and formulate mAbs to minimize attractive interactions at high concentrations is important for protein processing, stability, and administration, particularly in subcutaneous delivery, where high viscosities are often challenging. The strength of protein−protein interactions (PPIs) of an IgG1 and IgG4 monoclonal antibody (mAb) from low to high concentration was determined by static light scattering (SLS) and used to understand viscosity data. The PPI were tuned using NaCl and five organic ionic co-solutes. The PPI strength was quantified by the normalized structure factor S(0)/S(0) HS and Kirkwood−Buff integral G 22 /G 22,HS (HS = hard sphere) determined from the SLS data and also by fits with (1) a spherical Yukawa potential and (2) an interacting hard sphere (IHS) model, which describes attraction in terms of hypothetical oligomers. The IHS model was better able to capture the scattering behavior of the more strongly interacting systems (mAb and/or co-solute) than the spherical Yukawa potential. For each descriptor of PPI, linear correlations were obtained between the viscosity at high concentration (200 mg/mL) and the interaction strengths evaluated both at low (20 mg/mL) and high concentrations (200 mg/mL) for a given mAb. However, the only parameter that provided a correlation across both mAbs was the oligomer mass ratio (m oligomer /m monomer+dimer ) from the IHS model, indicating the importance of self-association (in addition to the direct influence of the attractive PPI) on the viscosity.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.